MDT

96.73

0%↓

146.55

-0.01%↓

VEEV

222.95

-3.43%↓

HQY

85.9

+2.08%↑

PHR.US

16.24

-1.81%↓

MDT

96.73

0%↓

146.55

-0.01%↓

VEEV

222.95

-3.43%↓

HQY

85.9

+2.08%↑

PHR.US

16.24

-1.81%↓

MDT

96.73

0%↓

146.55

-0.01%↓

VEEV

222.95

-3.43%↓

HQY

85.9

+2.08%↑

PHR.US

16.24

-1.81%↓

MDT

96.73

0%↓

146.55

-0.01%↓

VEEV

222.95

-3.43%↓

HQY

85.9

+2.08%↑

PHR.US

16.24

-1.81%↓

MDT

96.73

0%↓

146.55

-0.01%↓

VEEV

222.95

-3.43%↓

HQY

85.9

+2.08%↑

PHR.US

16.24

-1.81%↓

Home・Stock List・Savara Inc

Savara Inc

Open

SectorHealthcare

6.01 5.25

Buy Sell

Overview

Share price change

24h

Current

Min

5.72

Max

6.04

Key metrics
By Trading Economics
Income	840K -30M
EPS	-0.14
Employees	59
EBITDA	841K -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+76.26% upside

Dividends
By Dow Jones
Next Earnings	26 Mar 2026

Market Stats
By TradingEconomics
Market Cap	369M 1.2B
Previous open	0.76
Previous close	6.01

News Sentiment

By Acuity

31%

69%

86 / 361 Healthcare

Technical Score

By Trading Central

Confidence

Neutral Evidence

2.76 / 2.84 Support & Resistance

Savara Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Jan 2026, 19:05 UTC

Major Market Movers

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 Jan 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 Jan 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 Jan 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 Jan 2026, 23:13 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 Jan 2026, 23:10 UTC

Acquisitions, Mergers, Takeovers

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 Jan 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 Jan 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 Jan 2026, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 Jan 2026, 21:20 UTC

Acquisitions, Mergers, Takeovers

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 Jan 2026, 21:15 UTC

Acquisitions, Mergers, Takeovers

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 Jan 2026, 21:08 UTC

Acquisitions, Mergers, Takeovers

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 Jan 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 Jan 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 Jan 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 Jan 2026, 19:08 UTC

Acquisitions, Mergers, Takeovers

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 Jan 2026, 19:03 UTC

Earnings

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 Jan 2026, 18:50 UTC

Earnings

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 Jan 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 Jan 2026, 17:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

13 Jan 2026, 17:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 Jan 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 Jan 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 Jan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 Jan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 Jan 2026, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Basic Materials Roundup: Market Talk

13 Jan 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 Jan 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer Comparison

Price change

Savara Inc Forecast

Price Target

By TipRanks

76.26% upside

12 Months Forecast

Average 10.17 USD 76.26%

High 11 USD

Low 9 USD

Based on 6 Wall Street analysts offering 12 month price targets forSavara Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Savara Inc - Dist in the past 3 months.

Technical Score

By Trading Central

2.76 / 2.84Support & Resistance

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Sentiment

By Acuity

86 / 361 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.